MENU
+Compare
CARA
Stock ticker: NASDAQ
AS OF
Apr 15 closing price
Price
$5.32
Change
-$0.23 (-4.14%)
Capitalization
24.33M

CARA Cara Therapeutics Inc Forecast, Technical & Fundamental Analysis

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus... Show more

Industry: #Biotechnology
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CARA with price predictions
Apr 14, 2025

CARA sees its Stochastic Oscillator climbs out of oversold territory

On April 09, 2025, the Stochastic Oscillator for CARA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 14, 2025. You may want to consider a long position or call options on CARA as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CARA just turned positive on April 14, 2025. Looking at past instances where CARA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

CARA moved above its 50-day moving average on April 14, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CARA advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 114 cases where CARA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CARA moved out of overbought territory on March 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The 10-day moving average for CARA crossed bearishly below the 50-day moving average on April 09, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CARA broke above its upper Bollinger Band on March 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CARA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.113) is normal, around the industry mean (13.464). P/E Ratio (0.000) is within average values for comparable stocks, (63.084). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.770). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (3.401) is also within normal values, averaging (249.955).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CARA is expected to report earnings to fall 11.11% to -23 cents per share on November 29

Cara Therapeutics Inc CARA Stock Earnings Reports
Q3'24
Est.
$-0.24
Q2'24
Missed
by $0.01
Q1'24
Missed
by $0.16
Q4'23
Missed
by $0.14
Q3'23
Est.
$-0.52
The last earnings report on August 05 showed earnings per share of -27 cents, missing the estimate of -25 cents. With 237.14K shares outstanding, the current market capitalization sits at 24.33M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Atlantic Street
Phone
+1 203 406-3700
Employees
55
Web
https://www.caratherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL202.524.37
+2.21%
Apple
GME26.980.58
+2.20%
GameStop Corp
BTC.X84542.390000857.406250
+1.02%
Bitcoin cryptocurrency
SPY539.125.18
+0.97%
SPDR® S&P 500® ETF
TSLA252.350.04
+0.02%
Tesla

CARA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CARA has been loosely correlated with GPCR. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CARA jumps, then GPCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARA
1D Price
Change %
CARA100%
+13.26%
GPCR - CARA
39%
Loosely correlated
+19.18%
ASPHF - CARA
35%
Loosely correlated
N/A
XNCR - CARA
31%
Poorly correlated
+4.68%
PRME - CARA
31%
Poorly correlated
N/A
BEAM - CARA
30%
Poorly correlated
+9.89%
More